ADReCS

Pharmaceutical Information

Drug Name	Lithium carbonate
Drug ID	BADD_D01303
Description	Lithium has been used to treat manic episodes since the 19th century[A176642]. Though it is widely used, its mechanism of action is still unknown[FDA Label][A14585,A176642,A176651,L5843]. Lithium carbonate has a narrow therapeutic range and so careful monitoring is required to avoid adverse effects[FDA Label].
Indications and Usage	Lithium is used as a mood stabilizer, and is indicated for the treatment of manic episodes and maintenance of bipolar disorder[FDA Label].
Marketing Status	approved
ATC Code	Not Available
DrugBank ID	DB14509
KEGG ID	D00801
MeSH ID	D016651
PubChem ID	11125
TTD Drug ID	D04UUH
NDC Product Code	31722-546; 62332-148; 62756-430; 63187-304; 64980-205; 68462-221; 70518-0608; 70518-2312; 70518-2345; 70518-3565; 72789-171; 72789-172; 31722-544; 62332-014; 68071-2714; 0054-8531; 46708-303; 55154-4920; 63629-1916; 0378-1450; 70518-0668; 70518-3681; 0054-4527; 62332-013; 68462-220; 68462-222; 68462-223; 70518-0437; 70518-2699; 68084-655; 70518-1434; 0054-2531; 71335-0120; 0054-8528; 0615-8302; 50090-3917; 58118-0545; 0054-8526; 51079-142; 63629-1917; 68462-224; 71610-557; 72789-173; 39345-5104; 46708-305; 0378-1300; 64980-278; 70518-1753; 70518-2086; 0054-2526; 31722-545; 50090-1470; 62332-015; 62559-280; 0054-0020; 68428-481; 0054-2527; 72789-174; 82388-001; 46708-148; 50090-6052; 64117-256; 0054-0021; 68084-640; 70518-0904; 70518-1481; 0054-8527; 66039-947; 73309-248; 23155-763; 42291-496; 43063-901; 46708-304; 51079-180
UNII	2BMD2GNA4V
Synonyms	Lithium Carbonate \| Carbonate, Lithium \| Dilithium Carbonate \| Carbonate, Dilithium \| Lithane \| Lithium Bicarbonate \| Bicarbonate, Lithium \| Lithobid \| Lithonate \| CP-15,467-61 \| CP 15,467 61 \| CP15,46761 \| Micalith \| NSC-16895 \| NSC 16895 \| NSC16895 \| Priadel \| Quilinorm-retard \| Quilinorm retard \| Quilinormretard \| Eskalith \| Lithotabs

Chemical Information

Molecular Formula	CLi2O3
CAS Registry Number	554-13-2
SMILES	[Li+].[Li+].C(=O)([O-])[O-]
Chemical Structure

ADRs Induced by Drug

*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.

ADR Term	ADReCS ID	ADR Frequency (FAERS)	ADR Severity Grade (FAERS)	ADR Severity Grade (CTCAE)
Rhabdomyolysis	15.05.05.002	0.000803%
Salivary gland enlargement	07.06.03.002	-	-	-
Salivary hypersecretion	07.06.01.009	0.000803%		-
Schizoaffective disorder	19.03.02.002	0.000535%		-
Seizure	17.12.03.001	0.001874%
Serotonin syndrome	12.03.01.041; 15.05.04.016; 17.05.02.004	0.000535%		-
Sexual dysfunction	19.08.05.002; 21.03.02.003	-	-	-
Shock	24.06.02.002	-	-	-
Sinus arrhythmia	02.03.03.008	-	-	-
Sinus bradycardia	02.03.03.009	0.001071%
Skin disorder	23.03.03.007	-	-	-
Skin ulcer	23.07.03.003; 24.04.03.007	-	-
Sluggishness	08.01.01.004	-	-	-
Somnolence	17.02.04.006; 19.02.05.003	0.004604%
Speech disorder	17.02.08.003; 19.19.02.002; 22.12.03.027	0.000803%		-
Status epilepticus	17.12.03.005	0.001606%		-
Stupor	17.02.04.007; 19.02.05.004	-	-	-
Suicide attempt	19.12.01.004	0.003212%
Swelling	08.01.03.015	-	-	-
Syncope	02.11.04.015; 17.02.04.008; 24.06.02.012	-	-
Tachycardia	02.03.02.007	0.001071%		-
Tardive dyskinesia	17.01.02.012	0.000535%		-
Testicular pain	21.13.01.005	0.000535%
Therapeutic response decreased	08.06.01.016	-	-	-
Thinking abnormal	17.02.05.023; 19.10.03.001	0.000535%		-
Thirst	08.01.09.021; 14.03.02.007	-	-	-
Thyroid disorder	05.02.01.002	0.001446%		-
Thyroiditis	05.02.04.001	0.001338%		-
Thyrotoxic crisis	05.02.02.004; 06.09.04.004; 14.11.01.016; 19.07.03.006	0.001606%		-
Tic	17.02.05.024; 19.11.04.001	-	-	-

The 8th Page First Pre 8 9 10 11 Next Last Total 11 Pages